Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACBMNC for Prevention of BPD in Extremely Preterm Neonates
NCT04440670Phase 3Unknown
- Sponsor
- Guangdong Women and Children Hospital
- Start
- Jun 2020
- Primary completion
- Dec 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of autologous cord blood mononuclear cells in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by Guangdong Women and Children Hospital. Primary endpoint: Survival without bronchopulmonary dysplasia. Status: unknown.
02
Drugs
autologous cord blood mononuclear cells
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT04440670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04440670.